HONG KONG - Incyte Corp. entered a collaboration and licensing deal to flip its greater China rights to an investigational anti-PD-1 monoclonal antibody to Zai Lab Ltd., of Shanghai. The candidate, INCMGA-0012, is currently being evaluated as a monotherapy in registration-directed trials for patients with MSI-high endometrial cancer, Merkel cell carcinoma and anal cancer.
HONG KONG – Terns Pharmaceuticals Inc., a company based in China and the U.S., entered a licensing and collaboration agreement with French company Genfit SA to develop and commercialize elafibranor, in development for nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC).
HONG KONG – Proteona Pte. Ltd., of Singapore, has launched the first commercial product designed to characterize both RNA and protein expression levels across thousands of single chimeric antigen receptor (CAR) T cells.
HONG KONG – Singapore-based Tessa Therapeutics Ltd. and China-Singapore Guangzhou Knowledge City (CSGKC) are committing a combined $120 million to establish a joint venture to advance cell therapies targeting prevalent cancers in China.
HONG KONG –Terns Pharmaceuticals Inc., a company based in China and the U.S., entered a licensing and collaboration agreement with French company Genfit SA to develop and commercialize elafibranor, in development for nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC).
Singapore-based Tessa Therapeutics Ltd. and China-Singapore Guangzhou Knowledge City are committing a combined $120 million to establish a joint venture to advance cell therapies targeting prevalent cancers in China.
Proteona Pte. Ltd., of Singapore, has launched the first commercial product designed to characterize both RNA and protein expression levels across thousands of single chimeric antigen receptor T cells.
